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Abstract
Background: To have a better understanding of the mechanisms of exercise limitation in mild-to-moderate chronic
obstructive pulmonary disease (COPD), we compared detailed respiratory physiology in patients with COPD and healthy
age- and sex-matched controls.
Methods: Data were collected during the pre-treatment, patient characterization phase of a multicenter, randomized,
double-blind, crossover study. Patients with COPD met Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 or 2
spirometric criteria, were symptomatic, and had evidence of gas trapping during exercise. All participants completed
pulmonary function and symptom-limited incremental treadmill exercise tests.
Results: Chronic activity-related dyspnea measured by Baseline Dyspnea Index was similarly increased in patients with
GOLD 1 (n = 41) and 2 (n = 63) COPD compared with controls (n = 104). Plethysmographic lung volumes were increased and
lung diffusing capacity was decreased in both GOLD groups. Peak oxygen uptake and work rate were reduced in both GOLD
groups compared with controls (p,0.001). Submaximal ventilation, dyspnea, and leg discomfort ratings were higher for a
given work rate in both GOLD groups compared with controls. Resting inspiratory capacity, peak ventilation, and tidal
volume were reduced in patients with GOLD 2 COPD compared with patients with GOLD 1 COPD and controls (p,0.001).
Conclusions: Lower exercise tolerance in patients with GOLD 1 and 2 COPD compared with controls was explained by
greater mechanical abnormalities, greater ventilatory requirements, and increased subjective discomfort. Lower resting
inspiratory capacity in patients with GOLD 2 COPD was associated with greater mechanical constraints and lower peak
ventilation compared with patients with GOLD 1 COPD and controls.
Trial Registration: ClinicalTrials.gov: NCT01072396
Citation: O’Donnell DE, Maltais F, Porszasz J, Webb KA, Albers FC, et al. (2014) The Continuum of Physiological Impairment during Treadmill Walking in Patients
with Mild-to-Moderate COPD: Patient Characterization Phase of a Randomized Clinical Trial. PLoS ONE 9(5): e96574. doi:10.1371/journal.pone.0096574
Editor: Marco Idzko, University Hospital Freiburg, Germany
Received February 3, 2014; Accepted April 9, 2014; Published May 1, 2014
Copyright:  2014 O’Donnell et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Pfizer Inc. Writing, editorial support, and formatting assistance was
provided by Jane M. Gilbert, BSc CMPP, of Envision Scientific Solutions, which was contracted, and compensated by BIPI and Pfizer Inc for these services. The
funders provided support in the form of salaries for authors QD, HAP, FCA, & AI but did not have any additional role in the study design, data collection and
analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.
Competing Interests: This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Pfizer Inc. Writing, editorial support, and formatting
assistance was provided by Jane M. Gilbert, BSc CMPP, of Envision Scientific Solutions, which was contracted, and compensated by BIPI and Pfizer Inc for these
services. DEO has served on advisory boards for Boehringer Ingelheim, GlaxoSmithKline, Pfizer, and Roche. He has received payment for lectures including service
on speakers’ bureaus from Boehringer Ingelheim, GlaxoSmithKline, and Pfizer. His institution has received grants from AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Novartis, Nycomed, and Pfizer. FM is a consultant for Boehringer Ingelheim. He has served on advisory boards for Boehringer Ingelheim,
GlaxoSmithKline, and Pfizer and has received payment for lectures including service on speakers’ bureaus from Boehringer Ingelheim, GlaxoSmithKline, Nycomed,
and Pfizer. His institution has received grants from Boehringer Ingelheim and GlaxoSmithKline. JP is a consultant for Boehringer Ingelheim. KAW has no conflicts
of interest to declare. FCA was an employee of Boehringer Ingelheim Pharmaceuticals, Inc, at the time of the study. QD is an employee of Boehringer Ingelheim
Pharmaceuticals, Inc. HAP is an employee of Boehringer Ingelheim Pharmaceuticals, Inc. AI was an employee of Pfizer Inc at the time of the study. RC is a
consultant for Boehringer Ingelheim, Forest, and Novartis. He has served on advisory boards for Boehringer Ingelheim and Forest. He has received payment for
lectures including service on speakers’ bureaus from AstraZeneca, Boehringer Ingelheim, Forest, Novartis, and Pfizer. He has received payment for development of
educational presentations from Boehringer Ingelheim. His institution has received grants from Boehringer Ingelheim, Forest, GlaxoSmithKline, and Novartis. There
are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data
and materials, as detailed online in the guide for authors.
* E-mail: odonnell@queensu.ca
" Membership of the 205.440 investigators is provided in the Acknowledgments.
` Formerly.
PLOS ONE | www.plosone.org 1 May 2014 | Volume 9 | Issue 5 | e96574
Introduction
The majority of patients with chronic obstructive pulmonary
disease (COPD) worldwide have mild-to-moderate disease severity
[1], yet these patients are less extensively studied than those with
severe disease. Population-based studies have shown that smokers
with milder COPD have increased mortality [2], increased
hospitalizations, decreased health-related quality of life [3,4],
increased activity-related dyspnea, and reduced daily physical
activity levels compared with non-smoking healthy individuals [5–
9]. Although evidence has recently emerged to support the link
between dyspnea and activity restriction in mild COPD [10,11], a
better understanding of the underlying pathophysiology is needed
to rationalize management strategies for symptomatic patients.
It is well established that apparently minor airflow obstruction
(as measured by spirometry) may obscure widespread damage to
the peripheral airways (,2 mm diameter), lung parenchyma, and
pulmonary vasculature [12]. Previous studies have revealed vast
pathophysiological heterogeneity in mild COPD and successfully
quantified the extent of small airway dysfunction and pulmonary
gas exchange abnormality at rest [13–15]. More recently, small
studies have shown that these physiological perturbations are
amplified during the stress of cycle ergometer exercise in mild
COPD. Thus, compared with age-matched healthy controls,
ventilatory requirements were consistently increased for a given
metabolic load and gas trapping was increased, suggesting
significant ventilation–perfusion abnormalities and small airway
dysfunction, respectively [10,11,16,17]. The current multicenter
study extends previous investigations in mild-to-moderate COPD
by providing comparisons of detailed pulmonary physiology in a
large number of patients with Global Initiative for Chronic
Obstructive Lung Disease (GOLD) spirometry grade 1 and 2
COPD [18] and healthy controls. We selected symptomatic
patients (reflective of group B in the 2014 GOLD recommenda-
tions [18]) and evidence of dynamic lung hyperinflation during
exercise, where pharmacologic treatment is more likely to be
beneficial. The latter criterion (dynamic hyperinflation) was
included because it is a marker of expiratory flow limitation
during exercise in symptomatic patients with COPD who have a
largely preserved forced expiratory volume in 1 s (FEV1)
[10,11,16,17]. Moreover, recent studies in symptomatic patients
with mild-to-moderate COPD have shown that measureable
dynamic hyperinflation was present in the vast majority of cases
[10,11,14,19]. In the current study, treadmill exercise was selected
rather than cycling because it is potentially more reflective of
common daily activity i.e., walking. Weight-bearing treadmill
exercise is fundamentally different from weight-supported cycling
in terms of the extent of metabolic loading, acid-base and
pulmonary gas exchange abnormalities, and locomotor muscle
recruitment pattern [20–22]. Therefore, it remains to be
determined if mechanical and gas exchange derangements exist
during walking in milder COPD, and if these are similar in
magnitude and direction to those previously documented during
cycle ergometry in this population.
Our main objective was to evaluate the continuum of
physiological heterogeneity during rest and exercise in symptom-
atic patients with GOLD 1 and 2 COPD who had demonstrable
gas trapping (inspiratory capacity [IC] decline $100 mL) during
exercise. Therefore, we compared resting pulmonary function and
ventilatory responses to treadmill exercise, including breathing
pattern, operating lung volumes, and dyspnea and leg discomfort,
in patients with GOLD 1 and 2 COPD and healthy controls
matched for age and sex. This prospective physiological study
represents the initial ‘‘patient characterization’’ phase of a
randomized, placebo-controlled study designed to evaluate the
Figure 1. Subject disposition during the characterization phase of the study. IET, incremental exercise testing. *Since 104 control subjects
had full characterization data available, only the first 104 patients with COPD, who were eligible for randomization, were age- and sex-matched with
the controls for characterization data analysis.
doi:10.1371/journal.pone.0096574.g001
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efficacy of tiotropium in patients with mild-to-moderate COPD.
Results of the treatment phase will be presented separately.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Protocol S1 and
Checklist S1.
Ethics Statement
The study was carried out in compliance with the approved
protocol, the principles laid down in the Declaration of Helsinki
version as of October 1996, and in accordance with the
International Conference on Harmonisation Tripartite Guidelines
for Good Clinical Practice. Written informed consent was
obtained from all participants; the study protocol, informed
consent, and patient information were reviewed and approved by
Table 1. Subject characteristics.
GOLD 1 GOLD 2 Control
n=41 n=63 n=104
Male 21 (51) 27 (43) 48 (46)
Female 20 (49) 36 (57) 56 (54)
Age (years) 59.967.7 58.668.2 58.868.4
Height (cm) 169.7610.6 167.668.3 167.9611.2
Weight (kg) 78.6614.6 80.2613.8 77.6616.1
Body mass index (kg/m2) 27.063.8 28.463.9 27.464.1
Race
Asian 0 (0) 0 (0) 2 (2)
Black 0 (0) 11 (17) 5 (5)
White 41 (100) 52 (83) 97 (93)
Alcohol status
Non-drinker 11 (27) 30 (48) 32 (31)
Average consumption{ 30 (73) 33 (52) 72 (69)
Employment status
No 28 (68) 48 (76) 49 (47)
Yes 13 (32) 15 (24) 55 (53)
Time since COPD diagnosis (years) 3.563.6 5.165.7 N/A
Smoking history (pack-years`) 46619*** 45622*** 0.961.4
Smoking status
Never smoked 0 (0) 0 (0) 97 (93)
Ex-smoker 23 (56) 26 (41) 7 (7)
Current smokers 18 (44) 37 (59) 0 (0)
Baseline Dyspnea Index focal score 6.961.5*** 7.161.9*** 11.461.0
Cough/sputum for 3 months for 2 years 27 (66) 42 (67) N/A
Most troublesome respiratory symptom
Shortness of breath 29 (71) 44 (70) N/A
Cough 8 (20) 9 (14) N/A
Wheezing 0 (0) 5 (8) N/A
Sputum 4 (10) 3 (5) N/A
Other 0 (0) 2 (3) N/A
Respiratory medications at baseline
Long-acting b2-agonist 1 (2) 9 (14) 0 (0)
Inhaled corticosteroid 0 (0) 8 (13) 0 (0)
Long-acting b2-agonist/inhaled corticosteroid combination 0 (0) 6 (10) 0 (0)
Anticholinergics 3 (7) 8 (13) 0 (0)
Short-acting muscarinic antagonist 2 (5) 4 (6) 0 (0)
Long-acting muscarinic antagonist
(tiotropium)
1 (2) 5 (8) 0 (0)
Data are presented as mean 6 standard deviation for continuous variables and number of patients (%) for categorical variables.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; N/A, not applicable.
***p,0.001 versus control, using a two-sample t-test with unequal variance.
{Drinks alcohol, but to an extent that would not interfere with participation in the trial.
`1 pack-year represents 20 cigarettes per day for 1 year.
doi:10.1371/journal.pone.0096574.t001
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the following local Institutional Review Boards/Independent
Ethics Committees: Chesapeake Research Review, Inc. (Colum-
bia, MD); The John F. Wolf, M.D. Human Subjects Committee of
the Los Angeles Biomedical Research Institute at Harbor UCLA
Medical Center (Torrance, CA); Partners Human Research
Committee (Boston, MA); Western Institutional Review Board
(Olympia, WA); Springfield Committee for Research Involving
Human Subjects (Springfield, IL); Trustees of Dartmouth College,
Dartmouth–Hitchcock Medical Center, Committee for the
Protection of Human Subjects (Hanover, NH); Saint Francis
Hospital and Medical Center Institutional Review Board (Hart-
ford, CT); McGill University Health Center Research Ethics
Office (Montreal, QC); Comite´ d’E´thique de la Recherche de
I’Institut Universitaire de Cardiologie et de Pneumologie de
Quebe´c (Que´bec, QC); Queen’s University, Health Sciences and
Affiliated Teaching Hospitals Research Ethics Board (Kingston,
ON); and Centre Hospitalier de l’Universite´ de Montreal
(CHUM) Research Ethics Committee (Montreal, QC).
Study Design
This was a multicenter, multinational (11 US and four Canada
sites), randomized, double-blind, two-period crossover study
(ClinicalTrials.gov identifier: NCT01072396). The current anal-
ysis covered the 2-week pre-treatment patient characterization
phase of the study (Visits 1–3) in which patients with COPD were
compared with control subjects. Participants completed symptom
and activity assessments, pulmonary function tests, and an
incremental cardiopulmonary exercise test (Visit 1) and constant
work rate tests (Visits 2 and 3). Constant work rate test data are not
presented here.
Participants
Study participants were males and females, age $40 years, with
a body mass index (BMI) 18–35 kg/m2. Patients with COPD met
the following inclusion criteria: current or ex-smokers with .10
pack-year history; post-bronchodilator FEV1/forced vital capacity
(FVC) ,70% and FEV1$50% of predicted normal at Visit 1;
clinically stable as defined by no exacerbations in the previous 6
weeks and ,3 exacerbations in the preceding year; symptomatic
as defined by a Baseline Dyspnea Index (BDI) [23] focal score #9
and/or daily cough with sputum for 3 months per year during $2
consecutive years; and $100 mL decrease in IC during treadmill
exercise, as evidence of dynamic lung hyperinflation. Decrease in
IC was measured as the difference between the last acceptable IC
Table 2. Pulmonary function.
GOLD 1 GOLD 2 Control
n=41 n=63 n=104
FEV1 post-bronchodilator (L) 2.6560.75*** 1.8460.46***
,### 3.1160.81
FEV1 post-bronchodilator (% predicted) 92610*** 6769***
,### 112615
FEV1/FVC post-bronchodilator (%) 6465*** 5668***
,### 8165
Pre-bronchodilator (Visit 1)
FEV1 (L) 2.4560.71*** 1.6760.48***
,### 3.0260.80
FEV1 (% predicted) 86612*** 60611***
,### 109615
FEV1/FVC (%) 6166*** 5569***
,### 7866
SVC (L) 4.0461.20 3.2360.87***,### 3.9961.04
IC (L) 2.9061.01 2.3560.64***,### 2.8660.84
IC (% predicted) 103622 89616***,### 106618
FRC (L) 3.7760.91*** 3.6560.81*** 2.9560.76
FRC (% predicted) 117624*** 118626*** 93618
RV (L) 2.6360.81*** 2.7760.72***,# 1.8160.58
RV (% predicted) 121638*** 130635***,# 84624
TLC (L) 6.6761.63*** 6.0161.11**,# 5.7761.36
TLC (% predicted) 111616*** 105614*** 99612
sRaw (cmH2O/L/s)
{ 12.065.7*** 14.8610.9***,# 7.264.7
sRaw (% predicted)
{ 2926144*** 3636267***,# 1766120
DLCO (mL/min/mmHg)
` 18.666.7*** 16.064.6***,# 22.966.7
DLCO (% predicted)
` 73620*** 65616***,# 92617
Data are presented as mean 6 standard deviation.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SVC, slow vital capacity; IC, inspiratory
capacity; FRC, functional residual capacity; RV, residual volume; TLC, total lung capacity; sRaw, specific airway resistance; DLCO, diffusing capacity of the lung for carbon
monoxide.
P-values are from a linear regression model, adjusted for age, sex, alcohol status, employment status, and body mass index.
**p,0.01 versus control;
***p,0.001 versus control.
#p,0.05 GOLD 1 versus GOLD 2;
###p,0.001 GOLD 1 versus GOLD 2.
{GOLD 1, n = 40; GOLD 2, n = 62.
`GOLD 2, n = 61.
doi:10.1371/journal.pone.0096574.t002
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maneuver during exercise and the average pre-exercise resting IC.
To meet the inclusion criteria patients had to demonstrate $
100 mL decrease in IC in two of three exercise tests during the
pre-treatment patient characterization phase (incremental [Visit 1]
or constant work rate [Visits 2 and 3]). A control group consisted
of healthy subjects that were age- and sex-matched to the patients
with COPD. Control subjects were non-smokers, i.e., no cigarettes
in the previous 2 years and ,1 pack-year smoking history.
Subjects were excluded if they had contraindications to exercise, a
condition that limited exercise ability, or if they required
supplemental oxygen. Patients with COPD were categorized into
two groups: GOLD 1 (post-bronchodilator FEV1/FVC ,0.7 and
FEV1 $80% of predicted normal) and GOLD 2 (post-broncho-
dilator FEV1/FVC ,0.7 and 50%# FEV1 ,80% of predicted
normal).
Respiratory medications permitted during the baseline period
included: albuterol meter-dose inhaler (100 mg/puff) as needed
(withheld 8 h prior to each visit); short-acting anticholinergics
(withheld 8 h prior to each visit); long-acting b2-agonists (withheld
36 h prior to each visit); antihistamines, mucolytics, and
antileukotrienes. Medications not permitted included: long-acting
anticholinergics (not allowed within 2 weeks of Visit 1), oral b-
adrenergics, b-blockers, cromolyn sodium/nedocromil sodium,
and methylxanthines.
Procedures
Pre-bronchodilator spirometry, body plethysmography, and
single-breath diffusing capacity of the lung for carbon monoxide
(DLCO) were measured according to recommended standards [24–
26]. Post-bronchodilator spirometry was measured after inhalation
of albuterol (400 mg). Predicted normal values for FEV1 were
calculated using European Community for Steel and Coal
equations [27].
Symptom-limited exercise tests were performed on an electron-
ically controlled treadmill using cardiopulmonary exercise testing
systems capable of measuring IC. The incremental test in patients
with COPD consisted of a 10 W/min protocol, which was
repeated at 15 W/min if peak work rate was $150 W. Control
subjects performed a 15 W/min protocol or repeated the test at
20 W/min if peak work rate was $200 W. All tests included a 3-
min warm-up (0.27 m/s, 0% grade) followed by stepwise increases
in work rate: speed increased linearly from 0.27 to 1.79 m/s, and
inclination was calculated based on speed, individual’s weight, and
desired work rate [28]. Exercise measurements included: meta-
bolic parameters; minute ventilation (V˙E); breathing pattern;
operating lung volumes; intensity of dyspnea and leg discomfort
rated using a modified 10-point Borg scale [29]; and locus of end-
exercise symptom limitation (dyspnea, leg discomfort, or both).
Maximum breathing capacity (MBC) was estimated as FEV1
Table 3. Peak symptom-limited incremental treadmill exercise.
GOLD 1 GOLD 2 Control
n =41 n=63 n=104
Work rate (W) 116642*** 106631*** 196667
Dyspnea Borg scale{ 5.662.5 5.562.4 5.062.8
Leg discomfort Borg scale{ 4.762.8 5.362.6 4.762.8
V˙O2 (L/min)
{ 1.8160.59*** 1.6260.41***,# 2.1760.70
V˙CO2 (L/min)
{ 1.9460.71*** 1.6960.47***,# 2.4660.79
V˙E/V˙CO2
{ 35.366.6*** 33.8612.1** 29.363.9
V˙E (L/min){ 67.1623.6 55.1615.4***,### 71.5623.4
Breathing reserve (L/min){ 25.6615.4*** 9.6614.3***,### 37.3619.9
V˙E/MBC (%){ 72614 87620***,### 66616
VT (L){ 1.9260.59*** 1.5760.44***,### 2.1760.66
Fb (breaths/min){ 35.467.6 35.767.3 33.466.6
TI/TTOT{ 0.4460.05 0.4160.06***,## 0.4560.06
IC (L) 2.6760.78** 2.1760.59***,### 2.9060.81
DIC peak–rest (L) –0.5260.44*** –0.4260.31*** 0.0160.39
IRV (L){ 0.7560.40 0.6060.40* 0.7360.36
EELV (L) 4.0061.11*** 3.8560.87*** 2.8760.78
SpO2 minimum (%)
{ 94.462.8 93.562.9** 94.962.7
Data are presented as mean 6 standard deviation.
GOLD, Global Initiative for Chronic Obstructive Lung Disease; V˙O2, oxygen uptake; V˙CO2, carbon dioxide production; V˙E, minute ventilation; MBC, maximum breathing
capacity; VT, tidal volume; Fb, breathing frequency; TI, inspiratory time; TTOT, total respiratory time; TI/TTOT, inspiratory duty cycle; IC, inspiratory capacity; D, change; IRV,
inspiratory reserve volume; EELV, end-expiratory lung volumes; SpO2, arterial oxygen saturation measured by pulse oximetry.
P-values are from a linear regression model, adjusted for age, sex, alcohol status, employment status, and body mass index.
*p,0.05 versus control;
**p,0.01 versus control;
***p,0.001 versus control
#p,0.05 GOLD 1 versus GOLD 2;
##p,0.01 GOLD 1 versus GOLD 2;
###p,0.001 GOLD 1 versus GOLD 2.
{GOLD 2, n = 62.
doi:10.1371/journal.pone.0096574.t003
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V˙E
multiplied by 35 [30], and breathing reserve at end-exercise was
calculated as MBC minus peak V˙E.
Statistical Analysis
The sample size of 100 was dictated by the requirements of the
study’s treatment phase. Assuming a 20% dropout rate, 124
patients needed to be randomized to ensure 100 completed the
treatment phase, providing 90% power to detect a 100 mL
difference in dynamic hyperinflation (change in IC) during
exercise from baseline, based on a correlation of 0.6 and a type
one error rate of 0.05 using a two-sided test of significance. In the
characterization phase, a control group of equal size (n = 100) was
included in the study design. Data are presented as means 6
standard deviation (SD), unless indicated otherwise. P-values are
based on either a two-sample t-test with unequal variance or from
a linear regression model, adjusted for age, sex, alcohol status,
employment status, and body mass index (smoking status and race
were not included in the model because of the small number of
participants in some categories). Fisher’s exact test was used to
analyze locus of symptom limitation during incremental treadmill
exercise. Statistical analyses were applied using SAS version 9.2
software (SAS Institute, Cary, NC, USA).
Results
Participants
Participants were enrolled into the study between March 16,
2010 and August 1, 2011, the first patient entered the treatment
phase on April 14, 2010 and the last completed on November 29,
2011. Participant disposition during the characterization phase is
presented in Figure 1. Of the 277 patients with COPD enrolled in
the study, 195 met GOLD 1 or 2 spirometric criteria and
performed an incremental treadmill exercise test. The reasons for
study participant exclusion are given in Figure 1. In total, there
were 151 screen failures and 126 patients with COPD eligible for
randomization into the treatment phase. In the overall patient
population, only 23% (38 out of 164 patients; 17 out of 65 [26%]
for GOLD 1 COPD and 21 out of 99 [21%] for GOLD 2 COPD)
were excluded for the sole reason of not meeting the operational
definition of dynamic lung hyperinflation (i.e., $100 mL decrease
in IC during at least two out of three of the baseline exercise tests).
Of the 121 control subjects enrolled in the study, 104 completed
the characterization phase. Only the first 104 patients with
COPD, who met the eligibility criteria and were randomized to
treatment, were therefore age- and sex-matched with the 104
control subjects for the characterization phase data analysis.
Demographic data for the study participants are given in Table 1.
The GOLD groups were well matched for baseline demographics.
Respiratory medication use at baseline was greater in patients with
Figure 2. Ventilatory parameters versus work rate during incremental treadmill exercise. (A) Minute ventilation (V˙E), (B) ventilatory
equivalent for carbon dioxide (V˙E/V˙CO2), and (C) ventilation as a fraction of estimated maximum breathing capacity (V˙E/MBC). Data are shown as mean
6 standard error. Data plotted at 0 watts are warm-up data (0.27 m/s), followed by points at standardized work rates and at peak exercise. *p,0.05
GOLD 1 and 2 versus controls at a standardized work rate; #p,0.05 GOLD 1 versus controls; {p,0.05 GOLD 2 versus controls (confidence intervals do
not overlap indicating p,0.05).
doi:10.1371/journal.pone.0096574.g002
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GOLD 2 compared with GOLD 1 COPD. BDI focal scores were
similarly reduced in both GOLD groups compared with controls
(p,0.001). The frequency of troublesome respiratory symptoms
was similar in the two GOLD groups.
Pulmonary Function
Pulmonary function data are shown in Table 2. Both GOLD
groups had a significantly greater functional residual capacity
(FRC) and residual volume (RV) compared with controls (p,
0.001). Compared with controls, IC and slow vital capacity (SVC)
at rest were significantly lower in patients with GOLD 2 COPD
(p,0.001), but not in patients with GOLD 1 COPD. Specific
airway resistance was significantly higher (p,0.001) and DLCO
significantly lower (p,0.001) in both GOLD groups compared
with controls.
Incremental Exercise
Peak exercise data are shown in Table 3. Peak work rate was
significantly lower in both GOLD groups compared with controls
(p,0.001), but was similar in GOLD 1 and 2. Peak oxygen uptake
(V˙O2) and carbon dioxide production (V˙CO2) were significantly
lower in both GOLD groups compared with controls (p,0.001),
and were significantly lower in GOLD 2 compared with GOLD 1
(p,0.05). Peak V˙E was significantly reduced in GOLD 2
compared with the GOLD 1 and control groups (p,0.001), but
GOLD 1 was similar to the controls. Both GOLD groups had
significantly greater V˙E and ventilatory equivalents for carbon
dioxide (V˙E/V˙CO2) at rest and at any given work rate during
exercise compared with controls (Figure 2). V˙E/MBC at rest and
throughout exercise was also significantly greater in both GOLD
groups compared with controls, and was higher in GOLD 2
compared with GOLD 1 (Figure 2). Minimum oxygen saturations
were not significantly different in GOLD 1 compared with GOLD
2 and controls, but were lower by 1.4% in GOLD 2 compared
with controls (p,0.01) (Table 3).
In accordance with subject inclusion criteria, dynamic hyper-
inflation was shown in both GOLD groups as a significant
decrease in IC from rest to peak exercise; whereas, the controls did
not change IC significantly during exercise (Table 3). IC values at
rest and throughout exercise were similar in the GOLD 1 and
control groups, but were significantly smaller in the GOLD 2
group (Figure 3). The GOLD 2 group also had a significantly
smaller inspiratory reserve volume (IRV) than both the GOLD 1
and control groups at rest and at a given work rate during exercise,
but all groups reached a similar IRV at end-exercise (Figure 3).
End-expiratory lung volumes (EELV) and end-inspiratory lung
volumes (EILV) were significantly greater in patients with COPD
at rest and throughout exercise compared with controls (Figure 4).
To evaluate breathing pattern differences across groups,
measurements were plotted against V˙E (Figure 5). There was a
Figure 3. Breathing pattern and operating lung volume measurements versus work rate during incremental treadmill exercise. (A)
Breathing frequency (Fb), (B) tidal volume, (C) inspiratory capacity (IC), and (D) inspiratory reserve volume (IRV) showing that all three groups reach a
similar minimal value at end-exercise (shaded area). Data are shown as mean6 standard error. TLC, total lung capacity. *p,0.05 GOLD 1 and 2 versus
controls at a standardized work rate; #p,0.05 GOLD 1 versus controls; {p,0.05 GOLD 2 versus GOLD 1 and controls (confidence intervals do not
overlap indicating p,0.05).
doi:10.1371/journal.pone.0096574.g003
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significantly smaller tidal volume (VT) response in GOLD 2
compared with the GOLD 1 and control groups at peak exercise,
which was attributable to the smaller IC in the GOLD 2 group
(Table 3). The inspiratory duty cycle (inspiratory time/total
respiratory time [TI/TTOT]) at rest and throughout exercise was
also lower in GOLD 2 compared with the GOLD 1 and control
groups.
There were no significant differences across the groups in peak
symptom intensity ratings for dyspnea and leg discomfort (Table 3);
however, both GOLD groups had consistently higher values for
these parameters at a given work rate compared with controls
(Figure 6). There was a significant difference in the distribution of
reasons for stopping exercise across the groups (p,0.001). There
was a higher frequency of dyspnea, either alone or in combination
with leg discomfort in the GOLD 1 (88% [36/41]) and GOLD 2
(81% [51/63]) groups compared with controls (63% [65/104])
and a higher frequency of no dyspnea or leg discomfort in the
controls (14% [15/104] compared with the GOLD 1 (2% [1/41])
and GOLD 2 (0% [0/63]) groups.
Discussion
The main findings of this study are: (1) compared with healthy
participants, symptomatic patients with mild-to-moderate COPD
and measurable dynamic hyperinflation showed distinct physio-
logical impairment at rest and during exercise; (2) the magnitude
of dyspnea, leg discomfort, and exercise limitation was similar in
GOLD 1 and 2 COPD; (3) higher ventilatory requirements and
greater dynamic respiratory mechanical abnormalities were
present in both GOLD groups compared with controls; and 4)
increased constraints on VT expansion during exercise were
present in GOLD 2 COPD, in association with a reduced resting
IC in this group.
Healthy participants and patients with COPD were well
matched for age, sex, and BMI. Subjects in both GOLD groups
had a history of heavy smoking and reported moderate-to-severe
chronic dyspnea. Only a minority of patients received regular
pharmacotherapy for COPD. Of the three major respiratory
symptoms, the majority of patients reported that dyspnea was the
most troublesome (Table 1).
Contrary to our expectation, the nature and extent of lung
function impairment were remarkably similar in the two GOLD
groups. Both groups showed increased pulmonary gas trapping
(RV), increased lung hyperinflation (FRC) and reduced DLCO,
reflecting increased airway closure, alterations in the elastic
properties of the respiratory system and/or delayed mechanical
time constants for lung emptying, and disruption of the alveolar–
capillary surface area for gas exchange, respectively. However, in
contrast to patients with GOLD 2 COPD, those with GOLD 1
COPD had preserved resting IC and SVC. Thus, total lung
capacity (TLC), FRC, and RV increased in parallel in GOLD 1
COPD, whereas FRC and RV increased more relative to TLC in
GOLD 2 COPD. This preservation of IC and SVC in those with
milder airway obstruction (as measured by FEV1) has previously
been reported in cross-sectional studies in COPD [10,11,31,32],
and may have important implications for ventilatory capacity
during exercise and response to therapy.
Peak work rate and V˙O2 during incremental treadmill exercise
were reduced in both the GOLD groups compared with controls.
This magnitude of reduction in exercise performance in the
GOLD groups is considered clinically meaningful [33]. Ventila-
tory requirements were increased to a similar extent in the GOLD
groups compared with controls, by 5–10 L/min at a standardized
submaximal work rate, but represented a greater proportion of
MBC in patients with GOLD 2 COPD. The cause of the
additional ventilatory stimulation in COPD was not determined.
Figure 4. Operating lung volumes versus work rate during incremental treadmill exercise. End-expiratory lung volume (EELV) and end-
inspiratory lung volume (EILV) measurements were significantly greater (p,0.05) throughout exercise in GOLD 1 and 2 compared with controls (p-
values based on two-sample t-test with unequal variance). Data are shown as means. TLC, total lung capacity; IRV, inspiratory reserve volume; VT, tidal
volume.
doi:10.1371/journal.pone.0096574.g004
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Figure 5. Breathing pattern measurements versus minute ventilation during incremental treadmill exercise. (A) Tidal volume, (B)
breathing frequency (Fb), (C) mean inspiratory flow (tidal volume/inspiratory time [VT/TI]), and (D) inspiratory duty cycle (inspiratory time/total
respiratory time [TI/TTOT]). Data are shown as mean 6 standard error. *p,0.05 GOLD 2 versus GOLD 1 and controls at peak exercise (confidence
intervals do not overlap indicating p,0.05).
doi:10.1371/journal.pone.0096574.g005
Figure 6. Intensity ratings of (A) dyspnea and (B) leg discomfort versus work rate during incremental treadmill exercise. Data are
shown as mean 6 standard error. *p,0.05 GOLD 1 and GOLD 2 versus controls at a standardized work rate; #p,0.05 GOLD 1 versus controls
(confidence intervals do not overlap indicating p,0.05).
doi:10.1371/journal.pone.0096574.g006
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Many patients in both GOLD groups had physiological features of
emphysema (i.e., reduced DLCO and increased FRC), which is
known to be associated with disruption of pulmonary vascular
beds. V˙E/V˙CO2 was elevated at rest and throughout exercise in the
GOLD groups compared with controls, suggesting increased
inefficiency of CO2 elimination related to an increased physiolog-
ical dead space. However, arterial partial pressure of CO2
measurements would be required to evaluate such abnormalities
of pulmonary gas exchange more accurately. In accordance with
the study of Barbera et al. [13], there was no significant arterial O2
desaturation at peak exercise in either GOLD group. Other
possible contributors to increased V˙E, such as earlier metabolic
acidosis due to skeletal muscle deconditioning (with increased
afferent sensory inputs), reduced inspiratory muscle strength, or
occult cardiovascular impairment, were not quantified in this study
[34–37].
In accordance with the selection criteria, all study patients with
COPD showed evidence of dynamic lung hyperinflation during
exercise. This criterion was met in 77% of those originally
screened, who met all the other inclusion criteria, i.e., 23% of
otherwise eligible patients were excluded because of a lack of
dynamic hyperinflation. Breathing pattern alterations during
exercise were more pronounced in the GOLD 2 group because
of the decreased resting IC. This group had a relatively diminished
breathing reserve as crudely measured by the MBC minus peak
V˙E difference. Moreover, such patients reached a minimal IRV of
0.6 L and a VT/IC ratio exceeding 70% at a peak V˙E of only
55 L/min. The reduced VT expansion in the GOLD 2 group
compared with the GOLD 1 group and controls was associated
with a reduced TI/TTOT and lack of a compensatory increase in
mean inspiratory flow rate. It is not clear if these differences in
breathing pattern reflect the imposed restrictive mechanics
because of high lung volumes, central neural inhibition of the
drive to breathe as a result of the vagal inflation reflex, a
compensation strategy to minimize discomfort associated with
increased elastic loading, shallow breathing as a result of increased
inspiratory muscle dysfunction [37], or some combination of these.
The low IRV at a relatively low peak V˙E and power output in
patients with GOLD 2 COPD, indicates that EILV was positioned
close to TLC and the upper alinear extreme of the respiratory
system’s pressure–volume relation where elastic loading of
respiratory muscles is increased. Collectively, our results suggest
that critical mechanical constraints and the associated severe
breathing discomfort at a relatively low peak V˙E may have
contributed to exercise limitation in patients with GOLD 2
COPD. The preservation of resting IC in patients with GOLD 1
COPD compared with those with GOLD 2 COPD, allowed
greater VT expansion and the attainment of a significantly higher
peak V˙E before the onset of intolerable dyspnea.
At the limits of tolerance, all groups reported severe dyspnea
and leg discomfort, although these symptoms occurred at lower
peak work rates in the GOLD groups compared with controls.
Dyspnea and leg discomfort ratings were increased throughout
exercise in both GOLD groups compared with controls. Previ-
ously, we postulated that increased dyspnea in patients with mild-
to-moderate COPD compared with healthy individuals ultimately
reflects the increased contractile respiratory muscle effort (and
increased central corollary discharge) associated with increased V˙E
and the increased resistive and elastic loads on the respiratory
muscles [11,17]. It is noteworthy that leg discomfort intensity
ratings were broadly similar in magnitude to the dyspnea intensity
ratings in both GOLD groups and were higher than in the control
group for a given work rate. This was unexpected as perceived leg
discomfort is thought to be less problematic during treadmill
exercise compared with cycle exercise [38]. One potential reason
for the higher than expected ratings of leg discomfort in this study
could be the relatively steep inclination that subjects were required
to walk using this incremental exercise protocol, especially those
with lower body weights. Alternatively (or in addition), there is
increasing evidence of measurable peripheral muscle dysfunction
in patients with COPD who have mild-to-moderate airway
obstruction [39,40].
Our strict selection criteria (i.e., the requirement for dynamic
hyperinflation to occur) could mean that our results may not be
generalizable to the broader COPD population with milder airway
obstruction, many of whom may be less symptomatic than our
study subjects. However, study exclusion solely due to a lack of
significant dynamic hyperinflation during exercise occurred in
only 23% of those meeting GOLD 1 or 2 spirometric criteria that
performed the baseline exercise tests. A focus on symptomatic
patients who have documented impairment of respiratory
mechanics is justified, as this was the primary outcome measure
of interest in the subsequent intervention phase of the study. The
lack of a detailed evaluation of pulmonary gas exchange in this
study means that the mechanism of the increased ventilatory
demand in COPD remains unresolved.
In conclusion, this study is the first to elucidate the nature and
extent of physiological impairment during treadmill exercise in a
sizeable population of symptomatic patients with mild-to-moder-
ate COPD who have evidence of air trapping. Thus, it provides
new insights into mechanisms of poor exercise tolerance in this
group. Consistent ventilatory abnormalities during exercise in
both GOLD groups included higher ventilatory requirements for a
given power output and greater dynamic mechanical constraints.
Lower resting IC in the GOLD 2 group was associated with
altered breathing pattern responses during exercise with attain-
ment of minimal dynamic IRV (and associated severe dyspnea) at
a significantly lower peak V˙E than the GOLD 1 and control
groups. Thus, in the GOLD 2 group, the respiratory system had
approached or reached its physiological limits at the termination of
exercise. It remains to be determined whether bronchodilator
treatment, which improves respiratory mechanics, can increase
exercise tolerance in this little-studied population.
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